STOCK TITAN

TRACON Pharmaceuticals Inc - TCON STOCK NEWS

Welcome to our dedicated news page for TRACON Pharmaceuticals (Ticker: TCON), a resource for investors and traders seeking the latest updates and insights on TRACON Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TRACON Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TRACON Pharmaceuticals's position in the market.

Rhea-AI Summary
TRACON Pharmaceuticals, Inc. (TCON) announced financial results for Q4 and year-end 2023, highlighting progress in the ENVASARC trial with envafolimab. The company reported positive ORR data and plans to complete enrollment of 80 patients this quarter. TRACON aims to leverage its Product Development Platform for non-dilutive capital generation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
earnings
-
Rhea-AI Summary
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) will report its Q4 and year-end 2023 financial results on March 5, 2024. The company focuses on developing novel cancer therapeutics and partnering with life science firms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
conferences earnings
-
Rhea-AI Summary
TRACON Pharmaceuticals (NASDAQ: TCON) announced that the ongoing pivotal Phase 2 ENVASARC trial has enrolled more than 70 of the 80 planned patients in Cohort C of single agent envafolimab treatment at a dose of 600 mg subQ every three weeks. The objective response rate (ORR) by investigator review increased to 15% since the interim analysis in September. Full ENVASARC enrollment is expected in 1Q 2024, and final data is anticipated during 3Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Rhea-AI Summary
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) announces the licensing of its proprietary CRO-independent product development platform (PDP) to a clinical stage biotech company for a $3.0 million upfront payment. This move aims to allow other companies to benefit from TRACON's cost-efficient and shorter clinical trial timelines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
Rhea-AI Summary
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) announced their third quarter financial results, highlighting progress in the ENVASARC trial for envafolimab, a novel targeted cancer therapeutic. The company also reported upcoming milestones and positive financial results, including a net income of $10.8 million for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.75%
Tags
earnings
-
Rhea-AI Summary
TRACON Pharmaceuticals, Inc. will report its third quarter 2023 financial and operating results on November 9, 2023. The company utilizes a cost-efficient, CRO-independent product development platform for cancer therapeutics. A conference call will be held to discuss the financial results and provide an update on corporate activities. Registration is required to participate in the live call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
conferences earnings
Rhea-AI Summary
TRACON Pharmaceuticals announces positive results from ENVASARC Phase 2 trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
clinical trial
-
Rhea-AI Summary
TRACON Pharmaceuticals CEO to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
conferences
-
Rhea-AI Summary
TRACON Pharmaceuticals announces financial results for Q2 2023, including the collection of a $22M arbitration award. The company expects the award to extend its cash runway into early 2024. Interim efficacy assessment for ENVASARC trial expected later this quarter. Envafolimab shows a double-digit objective response rate (ORR) and is well tolerated. Upcoming milestones include completing accrual of the ENVASARC trial in Q4 2023 and final data from the trial in mid-2024. Cash position of $1.9 million at June 30, 2023, expected to fund the company into Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.92%
Tags
earnings
Rhea-AI Summary
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) will report its Q2 2023 financial and operating results on August 14, 2023, followed by a conference call to discuss the results and corporate activities. The company utilizes a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and partner with other life science companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
conferences earnings
TRACON Pharmaceuticals Inc

Nasdaq:TCON

TCON Rankings

TCON Stock Data

18.66M
41.55M
2.6%
11.88%
1%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
San Diego

About TCON

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w